Catheter Precision (VTAK) Investor presentation summary

Mission and corporate overview

• Focuses on advancing cardiac arrhythmia treatment through innovative medical devices and physician collaboration.

• Aims to improve patient outcomes, reduce healthcare costs, and enhance hospital productivity.

• Leadership has a strong track record of successful exits in the healthcare sector.

Market opportunity and growth

• Positioned in the multi-billion-dollar global electrophysiology and vascular closure markets, both projected for strong growth.

• Electrophysiology market expected to grow from $8.3B in 2023 to $15.1B by 2028 at a 13% CAGR.

• Catheter ablation market projected to reach $14.5B by 2032, growing at 13.5% CAGR.

• Vascular closure devices market valued at $1.9B in 2023, with 8.4% CAGR through 2030.

Product portfolio and innovation

• VIVO: Non-invasive 3D imaging system for ventricular arrhythmia localization, FDA cleared and CE marked, launched in 2023.

• LockeT: Suture retention device for vascular closure, FDA registered, launched in 2024, with multiple patent applications.

• Both products target improved clinical outcomes, cost savings, and workflow efficiency.